HRP20151255T1 - Izokinolinski modulatori atp-vezujuä†ih kasetnih transportera - Google Patents
Izokinolinski modulatori atp-vezujuä†ih kasetnih transportera Download PDFInfo
- Publication number
- HRP20151255T1 HRP20151255T1 HRP20151255TT HRP20151255T HRP20151255T1 HR P20151255 T1 HRP20151255 T1 HR P20151255T1 HR P20151255T T HRP20151255T T HR P20151255TT HR P20151255 T HRP20151255 T HR P20151255T HR P20151255 T1 HRP20151255 T1 HR P20151255T1
- Authority
- HR
- Croatia
- Prior art keywords
- aliphatic
- cycloaliphatic
- heterocycloaliphatic
- carbonyl
- carbonylamino
- Prior art date
Links
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 claims 45
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 31
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 24
- -1 sulfoxy Chemical group 0.000 claims 19
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 9
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- 125000003368 amide group Chemical group 0.000 claims 7
- 125000003435 aroyl group Chemical group 0.000 claims 7
- 125000004104 aryloxy group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims 5
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 5
- NWGPLYYBECWONP-UHFFFAOYSA-N (carbamoylamino) hydrogen sulfate Chemical compound NC(=O)NOS(O)(=O)=O NWGPLYYBECWONP-UHFFFAOYSA-N 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 claims 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
Claims (20)
1. Spoj s formulom (I):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da neovisno za svako pojavljivanje:
R1 je proizvoljno supstituirani C1-6 alifatski, proizvoljno supstituirani aril, proizvoljno supstituirani heteroaril, proizvoljno supstituirani 3 do 10 člani heterocikloalifatski, pod uvjetom da najmanje jedan R1 je proizvoljno supstituiran heterocikloalifatski, proizvoljno supstituirani aril, ili proizvoljno supstituirani heteroaril vezan na 1-položaj u izokinolinskom prstenu;
R2 je vodik, ili proizvoljno supstituirani C1-6 alifatski;
R3 i R'3 zajedno s atomom ugljika na koji su vezani tvore proizvoljno supstituiran C3-7 cikloalifatski;
R4 je proizvoljno supstituirani fenil; i
n je 1,
pri čemu proizvoljni supstituenti za aril su alifatski [npr., alkil, alkenil, ili alkinil]; cikloalifatski; (cikloalifatski)alifatski; heterocikloalifatski; (heterocikloalifatski)alifatski; aril; heteroaril; alkoksi; (cikloalifatski)oksi; (heterocikloalifatski)oksi; ariloksi; heteroariloksi; (aralifatski)oksi; (heteroaralifatski)oksi; aroil; heteroaroil; amino; okso (na ne-aromatskom karbocikličkom prstenu benzokondenziranog bicikličkog ili tricikličkog arila); nitro; karboksi; amido; acil [npr., alifatskikarbonil; (cikloalifatski)karbonil; ((cikloalifatski)alifatski)karbonil; (aralifatski)karbonil; (heterocikloalifatski)karbonil; ((heterocikloalifatski)alifatski)karbonil; ili (heteroaralifatski)karbonil]; sulfonil [npr., alifatskisulfonil ili aminosulfonil]; sulfinil [npr., alifatskisulfinil ili cikloalifatskisulfinil]; sulfanil [npr., alifatskisulfanil]; cijano; halo; hidroksi; merkapto; sulfoksi; urea; tiourea; sulfamoil; sulfamid; ili karbamoil;
pri čemu proizvoljni supstituenti za heteroaril su alifatski [npr., alkil, alkenil, ili alkinil]; cikloalifatski; (cikloalifatski)alifatski; heterocikloalifatski; (heterocikloalifatski)alifatski; aril; heteroaril; alkoksi; (cikloalifatski)oksi; (heterocikloalifatski)oksi; ariloksi; heteroariloksi; (aralifatski)oksi; (heteroaralifatski)oksi; aroil; heteroaroil; amino; okso (na ne-aromatskom karbocikličkom ili heterocikličkom prstenu bicikličkog ili tricikličkog heteroarila); karboksi; amido; acil [npr., alifatskikarbonil; (cikloalifatski)karbonil; ((cikloalifatski)alifatski)karbonil; (aralifatski)karbonil; (heterocikloalifatski)karbonil; ((heterocikloalifatski)alifatski)karbonil; ili (heteroaralifatski)karbonil]; sulfonil [npr., alifatskisulfonil ili aminosulfonil]; sulfinil [npr., alifatskisulfinil]; sulfanil [npr., alifatskisulfanil]; nitro; cijano; halo; hidroksi; merkapto; sulfoksi; urea; tiourea; sulfamoil; sulfamid; ili karbamoil;
pri čemu proizvoljni supstituenti za heterocikloalifatski su alifatski [npr., alkil, alkenil, ili alkinil], cikloalifatski, (cikloalifatski)alifatski, heterocikloalifatski, (heterocikloalifatski)alifatski, aril, heteroaril, alkoksi, (cikloalifatski)oksi, (heterocikloalifatski)oksi, ariloksi, heteroariloksi, (aralifatski)oksi, (heteroaralifatski)oksi, aroil, heteroaroil, amino, amido [npr., (alifatski)karbonilamino, (cikloalifatski)karbonilamino, ((cikloalifatski) alifatski)karbonilamino, (aril)karbonilamino, (aralifatski)karbonilamino, (heterocikloalifatski)karbonilamino, ((heterocikloalifatski) alifatski)karbonilamino, (heteroaril)karbonilamino, ili (heteroaralifatski)karbonilamino], nitro, karboksi [npr., HOOC-, alkoksikarbonil, ili alkilkarboniloksi], acil [npr., (cikloalifatski)karbonil, ((cikloalifatski) alifatski)karbonil, (aralifatski)karbonil, (heterocikloalifatski)karbonil, ((heterocikloalifatski)alifatski)karbonil, ili (heteroaralifatski)karbonil], nitro, cijano, halo, hidroksi, merkapto, sulfonil [npr., alkilsulfonil ili arilsulfonil], sulfinil [npr., alkilsulfinil], sulfanil [npr., alkilsulfanil], sulfoksi, urea, tiourea, sulfamoil, sulfamid, okso, ili karbamoil;
pri čemu izraz "alifatski' obuhvaća izraze alkil, alkenil, alkinil;
pri čemu proizvoljni supstituenti za alkilnu skupinu su halo, cikloalifatski [npr., cikloalkil ili cikloalkenil], heterocikloalifatski [npr., heterocikloalkil ili heterocikloalkenil], aril, heteroaril, alkoksi, aroil, heteroaroil, acil [npr., (alifatski)karbonil, (cikloalifatski)karbonil, ili (heterocikloalifatski)karbonil], nitro, cijano, amido [npr., (cikloalkilalkil)karbonilamino, arilkarbonilamino, aralkilkarbonilamino, (heterocikloalkil)karbonilamino, (heterocikloalkilalkil)karbonilamino, heteroarilkarbonilamino, heteroaralkilkarbonilamino], amino [npr., alifatskiamino, cikloalifatskiamino, ili heterocikloalifatskiamino], sulfonil [npr., alifatskisulfonil], sulfinil, sulfanil, sulfoksi, urea, tiourea, sulfamoil, sulfamid, okso, karboksi, karbamoil, cikloalifatskioksi, heterocikloalifatskioksi, ariloksi, heteroariloksi, aralkiloksi, heteroarilalkoksi, alkoksikarbonil, alkilkarboniloksi, ili hidroksil;
pri čemu proizvoljni supstituenti za alkenilnu skupinu su halo, cikloalifatski, heterocikloalifatski, aril, heteroaril, alkoksi, aroil, heteroaroil, acil [npr., (cikloalifatski)karbonil, ili (heterocikloalifatski)karbonil], nitro, cijano, acil [npr., alifatskikarbonil, cikloalifatskikarbonil, arilkarbonil, heterocikloalifatskikarbonil ili heteroarilkarbonil], amido [npr., (cikloalkilalkil)karbonilamino, arilkarbonilamino, aralkilkarbonilamino, (heterocikloalkil)karbonilamino, (heterocikloalkilalkil)karbonilamino, heteroarilkarbonilamino, heteroaralkilkarbonilamino alkilaminokarbonil, cikloalkilaminokarbonil, heterocikloalkilaminokarbonil, arilaminokarbonil, ili heteroarilaminokarbonil], amino [npr., alifatskiamino, ili alifatskisulfonilamino], sulfonil [npr., alkilsulfonil, cikloalifatskisulfonil, ili arilsulfonil], sulfinil, sulfanil, sulfoksi, urea, tiourea, sulfamoil, sulfamid, okso, karboksi, karbamoil, cikloalifatskioksi, heterocikloalifatskioksi, ariloksi, heteroariloksi, aralkiloksi, heteroarilalkoksi, alkoksikarbonil, alkilkarboniloksi, ili hidroksil;
pri čemu proizvoljni supstituenti za alkinilnu skupinu su aroil, heteroaroil, alkoksi, cikloalkiloksi, heterocikloalkiloksi, ariloksi, heteroariloksi, aralkiloksi, nitro, karboksi, cijano, halo, hidroksi, sulfo, merkapto, sulfanil [npr., alifatskisulfanil ili cikloalifatskisulfanil], sulfinil [npr., alifatskisulfinil ili cikloalifatskisulfinil], sulfonil [npr., alifatskisulfonil, alifatskiaminosulfonil, ili cikloalifatskisulfonil], amido [npr., aminokarbonil, alkilaminokarbonil, alkilkarbonilamino, cikloalkilaminokarbonil, heterocikloalkilaminokarbonil, cikloalkilkarbonilamino, arilaminokarbonil, arilkarbonilamino, aralkilkarbonilamino, (heterocikloalkil)karbonilamino, (cikloalkilalkil)karbonilamino, heteroaralkilkarbonilamino, heteroarilkarbonilamino ili heteroarilaminokarbonil], urea, tiourea, sulfamoil, sulfamid, alkoksikarbonil, alkilkarboniloksi, cikloalifatski, heterocikloalifatski, aril, heteroaril, acil [npr., (cikloalifatski)karbonil ili (heterocikloalifatski)karbonil], amino [npr., alifatskiamino], sulfoksi, okso, karboksi, karbamoil, (cikloalifatski)oksi, (heterocikloalifatski)oksi, ili (heteroaril)alkoksi;
pri čemu proizvoljni supstituenti za cikloalifatski su alifatski [npr., alkil, alkenil, ili alkinil], cikloalifatski, (cikloalifatski) alifatski, heterocikloalifatski, (heterocikloalifatski) alifatski, aril, heteroaril, alkoksi, (cikloalifatski)oksi, (heterocikloalifatski)oksi, ariloksi, heteroariloksi, (aralifatski)oksi, (heteroaralifatski)oksi, aroil, heteroaroil, amino, amido [npr., (alifatski)karbonilamino, (cikloalifatski)karbonilamino, ((cikloalifatski)alifatski)karbonilamino, (aril)karbonilamino, (aralifatski)karbonilamino, (heterocikloalifatski)karbonilamino, ((heterocikloalifatski)alifatski)karbonilamino, (heteroaril)karbonilamino, ili (heteroaralifatski)karbonilamino], nitro, karboksi [npr., HOOC-, alkoksikarbonil, ili alkilkarboniloksi], acil [npr., (cikloalifatski)karbonil, ((cikloalifatski) alifatski)karbonil, (aralifatski)karbonil, (heterocikloalifatski)karbonil, ((heterocikloalifatski)alifatski)karbonil, ili (heteroaralifatski)karbonil], cijano, halo, hidroksi, merkapto, sulfonil [npr., alkilsulfonil i arilsulfonil], sulfinil [npr., alkilsulfinil], sulfanil [npr., alkilsulfanil], sulfoksi, urea, tiourea, sulfamoil, sulfamid, okso, ili karbamoil.
2. Spoj prema zahtjevu 1, naznačen time da jedan R1 spojen na 1-položaju u izokinolinskom prstenu je supstituiran s 1, 2, ili 3 -ZDR9; pri čemu svaki ZD je neovisno veza ili proizvoljno supstituirani razgranati ili ravan C1-6 alifatski lanac pri čemu do dvije jedinice ugljika iz ZD su proizvoljno i neovisno zamijenjene s -CO-, -CONRE-, -CO2-, -O-, -NRECO-, -SO2-, -NRE-, -SO2NRE-, ili -NRESO2-; svaki R9 je neovisno RE, -OH, -NH2, -N(CH3)2, ili -N+(CH3)3; i svaki RE je neovisno vodik ili proizvoljno supstituirana C1-8 alifatska skupina.
3. Spoj prema zahtjevu 2, naznačen time da jedan R1 spojen na 1-položaju u izokinolinskom prstenu je fenil proizvoljno supstituiran s 1 ili 2 -ZDR9; heteroaril proizvoljno supstituiran s 1 -ZDR9; ili heterocikloalifatski, proizvoljno supstituiran s 1 -ZDR9.
4. Spoj prema zahtjevu 1, naznačen time da je jedan R1 spojen na 1-položaju u izokinolinskom prstenu odabran iz skupine koju čine
[image]
[image]
[image]
[image]
i
[image]
5. Spoj prema zahtjevu 1, naznačen time da R3 i R'3 zajedno s atomom ugljika na koji su vezani tvore C3-7 cikloalifatski, naročito ciklopropilni prsten.
6. Spoj prema zahtjevu 1, naznačen time da R4 je jedan odabran iz skupine koju čine
[image]
7. Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (III):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da neovisno za svako pojavljivanje:
RD je -ZDR9, gdje svaki ZD je neovisno veza ili proizvoljno supstituirani razgranati ili ravan C1-6 alifatski lanac pri čemu do dvije jedinice ugljika iz ZD su proizvoljno i neovisno zamijenjene s -CO-, - CONRE-, -CO2-, -NReCO2-, -O-, -NRECO-, -SO2-, -NRE-, -SO2NRE-, ili - NRESO2-;
R9 je RE, -OH, -NH2, -N(CH3)2, ili -N+(CH3)3;
RE je vodik ili proizvoljno supstituirana C1-8 alifatska skupina;
R2 je H ili C1-4 alifatski;
R3 i R'3 zajedno s atomom ugljika na koji su vezani tvore C3-7 cikloalifatski;
R4 je fenil, koji je proizvoljno supstituiran s 1, 2, ili 3 -ZCR8, pri čemu svaki ZC je neovisno veza ili proizvoljno supstituirani razgranati ili ravan C1-6 alifatski lanac pri čemu do dvije jedinice ugljika iz ZC su proizvoljno i neovisno zamijenjene s -O-; ili
R4 je fenil supstituiran s dva pojavljivanja -ZCR8, koji uzeti zajedno s atomima ugljika na koje su vezani, tvore 4-8 člani zasićeni, djelomično nezasićeni, ili aromatski prsten s do 2 atoma u prstenu koji su O; i R8 je proizvoljno supstituirana C1-8alifatska skupina.
8. Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu IV:
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da neovisno za svako pojavljivanje:
T je proizvoljno supstituiran C1-2 alifatski lanac, pri čemu svaka od jedinica ugljika je proizvoljno i neovisno zamijenjena s -CF2-;
R1' je vodik;
RD1 je vezan na ugljik broj 3" ili 4";
RD1 i RD2 su -ZDR9, pri čemu svaki ZD je neovisno veza ili proizvoljno supstituirani razgranati ili ravan C1-6 alifatski lanac pri čemu do dvije jedinice ugljika iz ZD su proizvoljno i neovisno zamijenjene s -CO-, - CONRE-, -CO2-, -O-, -NRECO-, -SO2-, -NRE-, -SO2NRE-, ili -NRESO2-;
R9 je RE, -OH, -NH2, -N(CH3)2, ili -N+(CH3)3;
ili RD1 i RD2, uzeti zajedno s atomima na koje su vezani, tvore 3-8 člani zasićeni, djelomično nezasićeni, ili aromatski prsten s do 3 člana prstena neovisno odabrana iz skupine koju čine O i NRE; i
RE je vodik ili proizvoljno supstituirana C1-8 alifatska skupina.
9. Spoj prema zahtjevu 8, naznačen time da T je odabran iz skupine koju čine -CH2- i -CF2-, ili pri čemu RD1 je -CO2H vezan na ugljik broj 3", RD2 je H, T je -CF2-, i R1' je H, ili pri čemu RD1 je -CO2H vezan na ugljik broj 4", RD2 je H, T je -CF2-, i R1' je H.
10. Spoj prema zahtjevu 8, naznačen time da RD1 i RD2, uzeti zajedno s atomima ugljika na koje su vezani, tvore proizvoljno supstituirani 3-8 člani zasićeni, djelomično nezasićeni, ili aromatski prsten s 0-2 atoma u prstenu neovisno odabrana iz skupine koju čine O i NRE.
11. Spoj prema zahtjevu 10, naznačen time da RD1 i RD2, uzeti zajedno s fenilom koji sadrži ugljikove atome 3" i 4", je
[image]
12. Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (VI):
[image]
naznačen time da
G je -O-, -CHR9-, ili -NR9-;
X je O ili H,H;
R10 i R11 su neovisno H ili alkoksi; ili R10 i R11 uzeti zajedno tvore
[image]
T je -CH2-, -CF2-, ili -C(CH3)2-;
R9 je vodik, proizvoljno supstituirana C1-8 alifatska skupina, ili proizvoljno supstituirani aril; i
R1' je H.
13. Spoj prema zahtjevu 12, naznačen time da R9 je alifatski, aril, metil ili fenil ili gdje R11 je alkoksi.
14. Spoj prema zahtjevu 12, naznačen time da G je -NR9-, R9 je metil, i X je H,H, ili pri čemu G je -NR9-, R9 je fenil, i X je O, ili pri čemu G je -CHR9-, R9 je fenil, i X je H,H, ili pri čemu G je -NR9-, R9 je H, i X je O, ili pri čemu G je -NR9-, R9 je metil, X je H,H, R11 je metoksi, i R10 je H, ili pri čemu G je - CHR9-, R9 je fenil, X je H,H, R11 je metoksi, i R10 je H, ili pri čemu G je -NR9-, R9 je H, X je O, R11 je metoksi, i R10 je H.
15. Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (VII):
[image]
naznačen time da Y je CH ili N pod uvjetom da najmanje jedan Y je N;
m je cijeli broj od 0 do uključivo 4;
T je proizvoljno supstituirani C1-2 alifatski lanac, gdje svaka od jedinica ugljika je proizvoljno i neovisno zamijenjena s -CF2-; i
R1' je vodik.
16. Spoj prema zahtjevu 15, naznačen time da T je -CH2- ili -CF2-, ili gdje meta Y je N, ili gdje m je 1.
17. Spoj prema zahtjevu 15, naznačen time da R1 je alkoksi, ili metoksi.
18. Spoj prema zahtjevu 1, naznačen time da spoj je jedan od slijedećih:
[image]
[image]
[image]
19. Farmaceutski pripravak naznačen time da sadrži:
(i) spoj prema zahtjevu 1; i
(ii) farmaceutski prihvatljiv nosač
20. Pripravak prema zahtjevu 19, naznačen time da nadalje sadrži mukolitičko sredstvo, bronhodilatator, antibiotik, protuinfektivno sredstvo, protuupalno sredstvo, modulator CFTR, ili prehrambeno sredstvo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98855907P | 2007-11-16 | 2007-11-16 | |
EP12181370.3A EP2578571B1 (en) | 2007-11-16 | 2008-11-14 | Isoquinoline modulators of ATP-binding cassette transporters |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20151255T1 true HRP20151255T1 (hr) | 2015-12-18 |
Family
ID=40303494
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140103AT HRP20140103T1 (hr) | 2007-11-16 | 2014-02-05 | Izokinolinski modulatori transportera atp-vežuä†e kazete |
HRP20151255TT HRP20151255T1 (hr) | 2007-11-16 | 2015-11-23 | Izokinolinski modulatori atp-vezujuä†ih kasetnih transportera |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140103AT HRP20140103T1 (hr) | 2007-11-16 | 2014-02-05 | Izokinolinski modulatori transportera atp-vežuä†e kazete |
Country Status (17)
Country | Link |
---|---|
US (4) | US8507524B2 (hr) |
EP (3) | EP3012250B1 (hr) |
JP (3) | JP5646338B2 (hr) |
CN (2) | CN102743385B (hr) |
AU (1) | AU2008322616B2 (hr) |
CA (1) | CA2705562C (hr) |
CY (1) | CY1115318T1 (hr) |
DK (2) | DK2217572T3 (hr) |
ES (3) | ES2556080T3 (hr) |
HK (3) | HK1148006A1 (hr) |
HR (2) | HRP20140103T1 (hr) |
HU (1) | HUE026334T2 (hr) |
NZ (2) | NZ585980A (hr) |
PL (2) | PL2217572T3 (hr) |
PT (2) | PT2578571E (hr) |
SI (2) | SI2578571T1 (hr) |
WO (1) | WO2009064959A1 (hr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
RU2006111093A (ru) | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
CA2545719A1 (en) * | 2003-11-14 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
ES2791303T3 (es) * | 2004-01-30 | 2020-11-03 | Vertex Pharma | Compuesto intermedio de moduladores de transportadores de casete de unión a ATP |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
WO2007021982A2 (en) | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP1945632B1 (en) * | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US20110064811A1 (en) | 2005-12-28 | 2011-03-17 | Patricia Hurter | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2006336504C9 (en) | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
ES2554353T3 (es) | 2006-04-07 | 2015-12-18 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
EP2158183A2 (en) * | 2007-05-25 | 2010-03-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
JP5389030B2 (ja) | 2007-08-24 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | (特に)嚢胞性線維症の処置に有用なイソチアゾロピリジノン |
NZ585980A (en) | 2007-11-16 | 2012-04-27 | Vertex Pharma | Isoquinoline modulators of atp-binding cassette transporters |
CA2706920C (en) | 2007-12-07 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
RS55360B1 (sr) | 2007-12-07 | 2017-03-31 | Vertex Pharma | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina |
US20100036130A1 (en) * | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
BRPI0820681A2 (pt) * | 2007-12-07 | 2019-09-24 | Vertex Pharma | formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico |
JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
NZ588006A (en) | 2008-03-31 | 2012-08-31 | Vertex Pharma | Pyridine derivatives as CFTR modulators, in particular N-(6-(benzylamino)-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamide |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
EP2349223A2 (en) | 2008-09-29 | 2011-08-03 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
UA104601C2 (uk) * | 2008-10-23 | 2014-02-25 | Вертекс Фармасьютікалз, Інкорпорейтед | Модулятори регулятора трансмембранної провідності при муковісцидозі |
MX2011009867A (es) | 2009-03-20 | 2012-01-12 | Vertex Pharma | Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
EP3828172A1 (en) | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
ES2579965T3 (es) | 2010-04-07 | 2016-08-17 | Vertex Pharmaceuticals Incorporated | Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico |
BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
CA2852991C (en) | 2011-11-08 | 2019-12-31 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
ES2852377T3 (es) | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
PT3068392T (pt) | 2013-11-12 | 2021-05-14 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr) |
DK3424534T3 (da) | 2014-04-15 | 2021-07-26 | Vertex Pharma | Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator |
GB201415381D0 (en) | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
LT3212189T (lt) | 2014-10-31 | 2020-11-25 | Abbvie Overseas S.A R.L. | Pakeisti chromanai ir naudojimo būdas |
BR112017010406B1 (pt) | 2014-11-18 | 2021-03-09 | Vertex Pharmaceuticals Incorporated | processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
CN105153013B (zh) * | 2015-09-16 | 2017-12-29 | 苏州昊帆生物科技有限公司 | 6‑溴异吲哚啉‑1‑酮的合成方法 |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
MX2019002396A (es) | 2016-08-31 | 2019-07-08 | Aerie Pharmaceuticals Inc | Composiciones oftalmicas. |
AU2017388300B2 (en) | 2016-12-28 | 2022-03-31 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
CN113943229A (zh) * | 2020-07-15 | 2022-01-18 | 天津师范大学 | 生物碱pulmonarin B的合成及在防治植物病毒和病菌病中的应用 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
KR20050061501A (ko) | 2002-09-30 | 2005-06-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 낭종 섬유증 트랜스막 전도도 조절기 단백질 억제제 및이의 용도 |
WO2004080972A1 (en) | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
SI2910551T1 (sl) | 2003-04-11 | 2017-07-31 | Ptc Therapeutics, Inc. | Spojine 1,2,4-oksadiazol benzojske kisline in njihova uporaba za zatiranje nesmiselne ter zdravljenje bolezni |
US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
WO2004111014A1 (en) | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
RU2006111093A (ru) | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
ZA200603515B (en) | 2003-10-08 | 2007-11-28 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
CA2545719A1 (en) | 2003-11-14 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
ES2791303T3 (es) * | 2004-01-30 | 2020-11-03 | Vertex Pharma | Compuesto intermedio de moduladores de transportadores de casete de unión a ATP |
US7522995B2 (en) | 2004-02-05 | 2009-04-21 | Nortrup Edward H | Method and system for providing travel time information |
CN1960966A (zh) | 2004-03-30 | 2007-05-09 | 加利福尼亚大学董事会 | 含酰肼cftr抑制剂化合物及其用途 |
CA2569402A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
CA2582885A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases |
JP5385605B2 (ja) | 2005-03-11 | 2014-01-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atp結合カセットトランスポーターのモジュレーター |
EP1863522A4 (en) | 2005-03-18 | 2010-11-10 | Univ California | CORRECTIVE TO THE PROCESSING OF MUTANT CFTR IMPACT COMPOUNDS AND ITS APPLICATIONS |
DK1874306T3 (da) | 2005-04-08 | 2012-10-01 | Ptc Therapeutics Inc | Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi |
WO2006127588A2 (en) | 2005-05-24 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
WO2007021982A2 (en) | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
ZA200803701B (en) | 2005-10-06 | 2009-08-26 | Vertex Pharma | Modulators of ATP-binding Cassette transporters |
EP1945632B1 (en) | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
AU2006331614A1 (en) | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of ABC transporters |
CA2635214A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
US20110064811A1 (en) | 2005-12-28 | 2011-03-17 | Patricia Hurter | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2006336504C9 (en) | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
ES2554353T3 (es) | 2006-04-07 | 2015-12-18 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
WO2007134279A2 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
JP5686596B2 (ja) | 2007-05-25 | 2015-03-18 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 |
US20110177999A1 (en) | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
JP5389030B2 (ja) | 2007-08-24 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | (特に)嚢胞性線維症の処置に有用なイソチアゾロピリジノン |
NZ583878A (en) | 2007-09-14 | 2012-10-26 | Vertex Pharma | Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR) |
US8163772B2 (en) | 2007-09-14 | 2012-04-24 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxypheny1]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
NZ585980A (en) | 2007-11-16 | 2012-04-27 | Vertex Pharma | Isoquinoline modulators of atp-binding cassette transporters |
BRPI0820681A2 (pt) | 2007-12-07 | 2019-09-24 | Vertex Pharma | formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
CA2706920C (en) | 2007-12-07 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
RS55360B1 (sr) | 2007-12-07 | 2017-03-31 | Vertex Pharma | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina |
ES2422741T3 (es) | 2007-12-13 | 2013-09-13 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
NZ588006A (en) | 2008-03-31 | 2012-08-31 | Vertex Pharma | Pyridine derivatives as CFTR modulators, in particular N-(6-(benzylamino)-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamide |
US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
CN102231990B (zh) | 2008-08-13 | 2013-09-25 | 沃泰克斯药物股份有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药 |
EP2349223A2 (en) | 2008-09-29 | 2011-08-03 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
DK2358680T3 (da) | 2008-10-23 | 2013-06-24 | Vertex Pharma | Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid |
CN102227430A (zh) | 2008-10-23 | 2011-10-26 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜传导调节因子的调节剂 |
UA104601C2 (uk) | 2008-10-23 | 2014-02-25 | Вертекс Фармасьютікалз, Інкорпорейтед | Модулятори регулятора трансмембранної провідності при муковісцидозі |
US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
WO2010078103A1 (en) | 2008-12-30 | 2010-07-08 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
MX2011009867A (es) | 2009-03-20 | 2012-01-12 | Vertex Pharma | Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
PL2408749T3 (pl) | 2009-03-20 | 2018-11-30 | Vertex Pharmaceuticals Incorporated | Modulatory transbłonowego regulatora przewodnictwa mukowiscydozy |
RU2543622C2 (ru) | 2009-09-17 | 2015-03-10 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения азабициклических соединений |
EP2490687A1 (en) | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
RU2553989C2 (ru) | 2009-10-23 | 2015-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза |
EP2491042A1 (en) | 2009-10-23 | 2012-08-29 | Vertex Pharmaceuticals Inc. | Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
EP2547658A1 (en) | 2010-03-19 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CA3016080C (en) | 2010-03-25 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
ES2579965T3 (es) | 2010-04-07 | 2016-08-17 | Vertex Pharmaceuticals Incorporated | Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico |
NZ603044A (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
NZ603042A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
CA2796602A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
AR081920A1 (es) | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
US20110288122A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical Compositions and Administrations Thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
BR112013004443A8 (pt) | 2010-08-23 | 2018-01-02 | Vertex Pharma | composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas |
CN103153286A (zh) | 2010-08-27 | 2013-06-12 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
AU2012332225A1 (en) | 2011-11-02 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases |
US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
CA2852991C (en) | 2011-11-08 | 2019-12-31 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
RU2644723C2 (ru) | 2012-01-25 | 2018-02-13 | Вертекс Фармасьютикалз Инкорпорейтед | Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
CA2890106C (en) | 2012-11-02 | 2022-08-02 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
DK3424534T3 (da) | 2014-04-15 | 2021-07-26 | Vertex Pharma | Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator |
MA54649A (fr) | 2014-10-06 | 2022-04-27 | Vertex Pharma | Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique |
EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
-
2008
- 2008-11-14 NZ NZ585980A patent/NZ585980A/en unknown
- 2008-11-14 CA CA2705562A patent/CA2705562C/en active Active
- 2008-11-14 ES ES12181370.3T patent/ES2556080T3/es active Active
- 2008-11-14 AU AU2008322616A patent/AU2008322616B2/en active Active
- 2008-11-14 EP EP15180766.6A patent/EP3012250B1/en active Active
- 2008-11-14 US US12/271,088 patent/US8507524B2/en active Active
- 2008-11-14 SI SI200831546T patent/SI2578571T1/sl unknown
- 2008-11-14 WO PCT/US2008/083517 patent/WO2009064959A1/en active Application Filing
- 2008-11-14 PT PT121813703T patent/PT2578571E/pt unknown
- 2008-11-14 CN CN201210243185.XA patent/CN102743385B/zh active Active
- 2008-11-14 PT PT08849242T patent/PT2217572E/pt unknown
- 2008-11-14 DK DK08849242T patent/DK2217572T3/da active
- 2008-11-14 ES ES08849242T patent/ES2445447T3/es active Active
- 2008-11-14 HU HUE12181370A patent/HUE026334T2/en unknown
- 2008-11-14 DK DK12181370.3T patent/DK2578571T3/en active
- 2008-11-14 SI SI200831147T patent/SI2217572T1/sl unknown
- 2008-11-14 EP EP20080849242 patent/EP2217572B1/en active Active
- 2008-11-14 NZ NZ59894108A patent/NZ598941A/xx unknown
- 2008-11-14 PL PL08849242T patent/PL2217572T3/pl unknown
- 2008-11-14 PL PL12181370T patent/PL2578571T3/pl unknown
- 2008-11-14 JP JP2010534201A patent/JP5646338B2/ja active Active
- 2008-11-14 CN CN2008801235011A patent/CN101952254B/zh active Active
- 2008-11-14 EP EP12181370.3A patent/EP2578571B1/en active Active
- 2008-11-14 ES ES15180766.6T patent/ES2658064T3/es active Active
-
2011
- 2011-03-03 HK HK11102136A patent/HK1148006A1/xx unknown
-
2013
- 2013-04-02 HK HK13104040.7A patent/HK1177137A1/xx unknown
- 2013-07-08 US US13/936,277 patent/US8722704B2/en active Active
-
2014
- 2014-02-03 CY CY20141100083T patent/CY1115318T1/el unknown
- 2014-02-03 JP JP2014018471A patent/JP5885359B2/ja active Active
- 2014-02-05 HR HRP20140103AT patent/HRP20140103T1/hr unknown
- 2014-03-21 US US14/221,537 patent/US9012473B2/en active Active
-
2015
- 2015-03-18 US US14/661,224 patent/US9522145B2/en active Active
- 2015-08-12 JP JP2015159316A patent/JP2015205936A/ja active Pending
- 2015-11-23 HR HRP20151255TT patent/HRP20151255T1/hr unknown
-
2016
- 2016-09-19 HK HK16110974.1A patent/HK1222847A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20151255T1 (hr) | Izokinolinski modulatori atp-vezujuä†ih kasetnih transportera | |
HRP20180916T1 (hr) | Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba | |
HRP20170154T1 (hr) | Analozi antibakterijskog aminoglikozida | |
RS52853B (en) | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | |
HRP20130202T1 (hr) | Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis | |
HRP20200995T1 (hr) | 19-nor neuroaktivni steroidi za metode liječenja | |
UY28747A1 (es) | Nuevo proceso para la sintesis y nueva forma cristalina de agomelatina y composiciones farmaceuticas que las contienen | |
HRP20161103T1 (hr) | Kemijski spojevi | |
HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
RS54876B1 (sr) | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih | |
HRP20230854T1 (hr) | Fap-aktivirana terapeutska sredstva i s njima povezane uporabe | |
JP2010235612A5 (hr) | ||
HRP20130942T1 (hr) | Aminodiazepini kao modulatori toll-u sliäśnih receptora | |
ES2670878T3 (es) | Cianometilpirazol carboxamidas como inhibidores de la Janus quinasa | |
WO2008042240A3 (en) | Enantiomerically pure phosphoindoles as hiv inhibitors | |
AR086977A1 (es) | Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen | |
HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
JP2013531031A5 (hr) | ||
AR087909A1 (es) | Composiciones farmaceuticas | |
HRP20130846T1 (hr) | Derivati indolizina i njihova uporaba u medicinske svrhe | |
JP2016505595A5 (hr) | ||
SI2935307T1 (en) | Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures | |
HRP20110885T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
ECSP088862A (es) | Formulaciones de dosificación sólida |